ReVive Biotechnology is Other Pharmaceuticals and Biotechnology in United States that focus on ischemic retinal conditions business. Founded in 2018. They cover business area such as developer, proprietary biotechnology, nanotechnology, application, ophthalmic diagnostic, oxygen delivery, various hypoxic tissue, ischemic retinal condition, retina treatment, diagnostic modality.
Other Pharmaceuticals and Biotechnology
2018
( 6 years old in 2024 )
Ischemic Retinal Conditions
-
4508 Southford Trace Drive
Champaign, IL 61822
United States
Private
developerproprietary biotechnologynanotechnologyapplicationophthalmic diagnosticoxygen deliveryvarious hypoxic tissueischemic retinal conditionretina treatmentdiagnostic modality
* We use standard office opening hours in near ReVive Biotechnology's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
ReVive Biotechnology is Other Pharmaceuticals and Biotechnology business from United States that founded in 2018 (6 years old in 2024), ReVive Biotechnology business is focusing on Ischemic Retinal Conditions.
ReVive Biotechnology headquarter office and corporate office address is located in 4508 Southford Trace Drive Champaign, IL 61822 United States.
ReVive Biotechnology was founded in United States.
In 2024, ReVive Biotechnology is currently focus on ischemic retinal conditions sector.
Above is snippet of Google Trends for "ischemic retinal conditions" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with ReVive Biotechnology, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
